Share on LinkedInShare on LinkedIn

ARTICLE · 26 APRIL 2023

Regeneron V. Mylan – Update On Aflibercept BPCIA Litigation

As we previously reported, Regeneron's BPCIA case against Mylan regarding Mylan's proposed aflibercept biosimilar is proceeding on an expedited schedule, with a two-week trial scheduled to begin on

United StatesIntellectual Property

As we previously reported, Regeneron's BPCIA case against Mylan regarding Mylan's proposed aflibercept biosimilar is proceeding on an expedited schedule, with a two-week trial scheduled to begin on June 12, 2023, less than a year from Regeneron's filing of its complaint in August 2022. The Court's scheduling order, issued in October 2022, required Regeneron to immediately identify six patents for the June trial from among the 24 patents originally listed in Regeneron's Complaint. The scheduling order also required that within 7 days of the Court's claim construction order, Regeneron must further limit the issues for the trial to three patents and no more than 25 claims. The court held a claim construction hearing on January 24, 2023, but has not yet issued a claim construction order.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from